title: Luteal phase support and severe ovarian hyperstimulation syndrome.
abstract: The incidence and statistical associations of the ovarian hyperstimulation syndrome (OHSS) were studied in 304 egg retrievals with gonadotrophin-releasing hormone agonist suppression, gonadotrophin administration and follicular aspiration. In addition to preserving corpus luteum function, the luteal phase administration of human chorionic gonadotrophin (HCG) was associated with a higher incidence of severe OHSS than was supplementation with progesterone alone (12 versus 0%, P less than 0.001). Severe OHSS occurred in 3.7% and 12% of retrievals without and with pregnancy respectively (P less than 0.01). Stepwise logistic regression showed that the occurrence of moderate or severe OHSS was statistically predicted by the log of the serum oestradiol on the day the initial HCG was given (P less than 0.0001), treatment with luteal phase HCG (P less than 0.0003), and fetal number (P less than 0.0079). In the late luteal phase of cycles without luteal HCG, the serum oestradiol concentration was one-tenth and the serum progesterone concentration was one-fifth of the luteal phase value with HCG support (P less than 0.001). Without luteal phase HCG, oestradiol was two-fold higher (P less than 0.001) and progesterone was 1.4-fold higher (P less than 0.005) in pregnant than in non-pregnant women. With luteal phase HCG, oestradiol was 1.4-fold higher in pregnant than in non-pregnant women (P less than 0.05), and progesterone was 1.7-fold higher (P less than 0.001). Oestradiol upper limits of 4400 and 14,700 pmol/l (1200 and 4000 pg/ml) for cycles with and without luteal phase HCG respectively correspond to approximately 5% risk of moderate or severe OHSS with a singleton pregnancy under these conditions.
authors.affiliation: Department of Obstetrics and Gynecology, Brown University Providence, RI.
authors.forename: N
authors.initials: N
authors.lastname: McClure
authors.forename: J
authors.initials: J
authors.lastname: Leya
authors.forename: E
authors.initials: E
authors.lastname: Radwanska
authors.forename: R
authors.initials: R
authors.lastname: Rawlins
authors.forename: R V
authors.initials: RV
authors.lastname: Haning
mesh_terms: D006063:Chorionic Gonadotropin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008183:Luteal Phase / Q000502:physiology*; D016471:Ovarian Hyperstimulation Syndrome / Q000503:physiopathology*; D011247:Pregnancy; D011374:Progesterone / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D006063:Chorionic Gonadotropin; D011374:Progesterone; D004958:Estradiol